Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Virginia Retirement Systems ET AL

Virginia Retirement Systems ET AL trimmed its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 7.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,800 shares of the specialty pharmaceutical company’s stock after selling 2,300 shares during the quarter. Virginia Retirement Systems ET AL owned about 0.05% of Supernus Pharmaceuticals worth $887,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in the company. Stifel Financial Corp increased its position in Supernus Pharmaceuticals by 18.9% in the 2nd quarter. Stifel Financial Corp now owns 17,351 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 2,761 shares during the period. Liberty Wealth Management LLC increased its position in Supernus Pharmaceuticals by 3,056.6% in the 2nd quarter. Liberty Wealth Management LLC now owns 5,019 shares of the specialty pharmaceutical company’s stock valued at $163,000 after acquiring an additional 4,860 shares during the period. Geode Capital Management LLC increased its position in Supernus Pharmaceuticals by 4.1% in the 2nd quarter. Geode Capital Management LLC now owns 905,691 shares of the specialty pharmaceutical company’s stock valued at $27,886,000 after acquiring an additional 36,067 shares during the period. Vanguard Group Inc. increased its position in Supernus Pharmaceuticals by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 5,484,424 shares of the specialty pharmaceutical company’s stock valued at $168,865,000 after acquiring an additional 29,869 shares during the period. Finally, Vident Investment Advisory LLC increased its position in Supernus Pharmaceuticals by 53.9% in the 2nd quarter. Vident Investment Advisory LLC now owns 15,283 shares of the specialty pharmaceutical company’s stock valued at $471,000 after acquiring an additional 5,351 shares during the period.

Separately, Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $35.00 target price on the stock in a research report on Friday, October 15th.

Shares of SUPN stock opened at $29.90 on Thursday. Supernus Pharmaceuticals, Inc. has a 1 year low of $17.20 and a 1 year high of $34.29. The stock has a market cap of $1.59 billion, a PE ratio of 16.16 and a beta of 1.22. The business’s fifty day moving average is $26.83 and its 200-day moving average is $28.73. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.05 and a current ratio of 2.26.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Wednesday, August 4th. The specialty pharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.26. Supernus Pharmaceuticals had a return on equity of 13.39% and a net margin of 17.55%. The company had revenue of $141.33 million for the quarter, compared to analysts’ expectations of $135.50 million. During the same period last year, the firm earned $0.65 EPS. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.02 earnings per share for the current year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Featured Story: What are Bollinger Bands?

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.